Skip to main content
. 2022 Jan 28;9:820725. doi: 10.3389/fsurg.2022.820725

Table 1.

Demographics of 330 gastrointestinal neuroendocrine carcinoma with bone metastasis at diagnosis.

Variable Value
Race
White 261 (79.1%)
Black 43 (13.0%)
Others 26 (7.9%)
Gender
Female 123 (37.3%)
Male 207 (62.7%)
Age (years)
≤60 125 (37.9%)
>60 205 (62.1%)
Tumor location
Colon and rectum 83 (25.2%)
Pancreas, liver, stomach 164 (49.7%)
Others 83 (25.2%)
Tumor size (cm)
<5 110 (33.3%)
≥5 85 (25.8%)
Unknown 135 (40.9%)
Surgery
Yes 34 (10.3%)
No 296 (89.7%)
Radiotherapy
Yes 108 (32.7%)
No 222 (67.3%)
Chemotherapy
Yes 180 (54.5%)
No 150 (45.5%)
Brain metastasis
No 294 (89.1%)
Yes 21 (6.4%)
Unknown 15 (4.5%)
Liver metastasis
No 73 (22.1%)
Yes 251 (76.1%)
Unknown 6 (1.8%)
Lung metastasis
No 234 (70.9%)
Yes 78 (23.6%)
Unknown 18 (5.5%)
Marital status
Married 183 (55.5%)
Others 131 (39.7%)
Unknown 16 (4.8%)
Dead
Yes 257 (77.9%)
No 73 (22.1%)
1-year OS rate 39.50%
1-year CSS rate 40.00%
3-year OS rate 16.70%
3-year CSS rate 17.00%

OS, overall survival; CSS, cancer-specific survival.